Early relapse identifies MCL patients with inferior survival after intensive or less intensive frontline therapy
David A. Bond(The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute), Jonathon B. Cohen(Emory University), Brian T. Hill(Cleveland Clinic), Alina S. Gerrie(University of British Columbia), Madelyn Burkart(Atrium Health Wake Forest Baptist), Mehdi Hamadani(Medical College of Wisconsin), Yazeed Sawalha(Cleveland Clinic), Stefan K. Barta(University of Pennsylvania), Kami J. Maddocks(The Ohio State University), Michael C. Churnetski(Emory University), James N. Gerson(UPMC Hillman Cancer Center), Peter Martin(Northwestern University), Jeffrey M. Switchenko(Emory University), Diego Villa(BC Cancer Agency), Bhaskar Kolla(University of Minnesota), Max J. Gordon(Oregon Health & Science University), Kristie A. Blum(Emory University), Subir Goyal(Emory University), Krithika Shanmugasundaram(National Cancer Institute), Veronika Bachanová(University of Minnesota), Alexey V. Danilov(City of Hope), Brad S. Kahl(UW Health University Hospital), Timothy S. Fenske(Medical College of Wisconsin), Mary‐Kate Malecek(Washington University in St. Louis), Steven Park(Levine Cancer Institute), Nilanjan Ghosh(Levine Cancer Institute), Natalie S. Grover(University of North Carolina at Chapel Hill), Talha Badar(Mayo Clinic in Florida), Christopher R. Flowers(The University of Texas MD Anderson Cancer Center), Narendranath Epperla(University of Utah), Oscar Calzada(Emory University), Stephanie Mathews(University of North Carolina at Chapel Hill), Reem Karmali(Northwestern University), Jin Guo(NewYork–Presbyterian Hospital), Edward Maldonado(University of California, San Francisco)
Cited by 41
Related Papers
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
|New England Journal of Medicine|2017|6k
Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1–2 trial
|The Lancet Oncology|2018|2.3k
Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2013|2.2k
Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2015|1.9k
KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma
|New England Journal of Medicine|2020|1.9k